Zydus Lifesciences gets US FDA nod for cancer drug
Zydus Lifesciences just scored a tentative green light from the US FDA for its generic version of olaparib, a targeted therapy used to treat several cancers linked to BRCA and HRR gene mutations.
While it can't hit US shelves until patents expire and final approval comes through, this is a big step—especially since the branded version, Lynparza, pulled in $1.38 billion in sales over the past year.
Zydus's financials are on the rise
This move puts Zydus in line to tap into a massive market once patents clear, showing how Indian pharma is stepping up globally.
Plus, Zydus isn't slowing down financially: their latest quarter saw revenue jump 17% and profits soar 39%, with shares closing strong at ₹943.80 on November 7.
If you're curious about how science and business collide—or where future jobs might be—this is one to watch.